Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280797 | 0.82 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL21537534 | 0.79 | MAP4K4 (0.59) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2117282 | 0.79 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15089237 | 0.78 | MAPT (0.52) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15617051 | 0.78 | CYP2A6 (0.69) | SMN1; SMN2MEN1KDM4EALDH1A1MAPT | |
| SCHEMBL903606 | 0.77 | NPC1 (0.95) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6682733 | 0.77 | NPC1 (0.95) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6679319 | 0.77 | NPC1 (0.95) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL13527439 | 0.77 | NPC1 (0.95) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15292158 | 0.76 | MEN1 (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| WO-2024058617-A1 | ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND | 일동제약(주) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006474-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006474-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010107244-A2 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | DOW ADVANCED DISPLAY MATERIALS, LTD. (KR) | 2010-09-23 | — | — | WO | disclosed |
| CN-1280289-C | Alkoxy carbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | HOFFMANN LA ROCHE (CH) | 2006-10-18 | — | — | CN | disclosed |
| CN-1494544-A | Alkoxy carbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | - | 2004-05-05 | — | — | CN | disclosed |
| US-5776858-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1998-07-07 | — | — | US | disclosed |
| CN-1153173-A | 1-azinyl-tetrazolinones compounds | BAYER AGROCHEM KK (JP) | 1997-07-02 | — | — | CN | disclosed |
| EP-0771797-A1 | 1-Azinyl-tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885NPC1 2436/4885SMN1; SMN2 3529/4885 |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ANO1, ANO2, CACYBP | RAB9A 2944/4885NPC1 2582/4885SMN1; SMN2 3761/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | RAB9A 519/4885NPC1 2436/4885SMN1; SMN2 3529/4885 |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | RAB9A 1848/4885NPC1 1752/4885SMN1; SMN2 1830/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | RAB9A 480/4885NPC1 2546/4885SMN1; SMN2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.